Allmed Solutions

Allmed Solutions R&D per Employee

R&D Spending per Employee of Allmed Solutions (ALMD.TA) as of Nov 12, 2026.

R&D per Employee

-ILS

Last updated:

R&D Spending per Employee of Allmed Solutions is 2026 - ILS. R&D Spending per Employee of Allmed Solutions was 2025 - ILS. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Allmed Solutions Stock analysis

What does Allmed Solutions do? Allmed Solutions Ltd, based in Caesarea, Israel, is listed on the stock market since 2007. The company develops, manufactures, and markets minimally invasive medical products globally. Its product portfolio includes Covered Stents for urinary and biliary conditions, Uro-Gynecology solutions for pelvic organ prolapse and incontinence, Type II Diabetes treatments like the Gastro-duodenal sleeve, and Cardiovascular devices such as the WIRION EPD System. These products address medical needs including pelvic organ prolapse, urinary incontinence, and carotid stenosis worldwide. Allmed Solutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Allmed Solutions stock

On Eulerpool you can find the complete historical development of R&D Spending per Employee Allmed Solutions since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Allmed Solutions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Allmed Solutions

All Key Metrics — Allmed Solutions